Gene activation, apolipoprotein A-I/high density lipoprotein, atherosclerosis prevention and longevity

Pharmacology and Toxicology

Volumn 81, Issue 2, 1997, Pages 57-64

  Luoma, Pauli V ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTICONVULSIVE AGENT; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; CLOFIBRATE; COLESTYRAMINE; DEXAMETHASONE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HORMONE; LIPOPROTEIN; MEVINOLIN; PHENOBARBITAL; PHENYTOIN; PRAVASTATIN; PREDNISONE; SIMVASTATIN;

ATHEROSCLEROSIS; GENE ACTIVATION; HUMAN; HYPERLIPIDEMIA; LONGEVITY; PRIORITY JOURNAL; REVIEW;

ANIMALIA;

EID: 0030787747     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1997.tb00032.x     Document Type: Review

References (71)

1. Amarasuriya, R. N., A. K. Gupta, M. Civen, T. Horng, T. Maeda & M. L. Kashyap: Ethanol stimulates A-I secretion by human hepatocytes: implications for a mechanism for atherosclerosis protection. Metabolism 1992, 41, 827-832.
2. Avogaro, P.: Familial hyperalphalipoproteinaemia. In: Clinical and metabolic aspects of high-density lipoprotiens. Eds.: N. E. Miller & G. J. Miller. Elsevier Science Publishers. Amsterdam. 1984, pp. 289-295.
3. Badimon, J. J. L. Badimon & V. Fuster: Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J. Clin. Invest. 1990, 85, 1234-1241.
4. Badimon, J. J., V. Fuster & L. Badimon: Role of high density lipoprotein in the regression of atherosclerosis Circulation 1992, 86 suppl. III, III-86- III-94.
5. Barter, P. J. & K.-A. Rye: High density lipoproteins and coronary-heart disease. Atherosclerosis 1996, 121, 1-12.
6. Bondjers, G., A. Gustafson, J. Kral, T. Schersten & L. Sjöström: Cholesterol content in arterial tissue in relation to serum lipoproteins in man. Artery 1976, 2, 200-207.
7. Calandre, S. & P. Tarugi: Synthesis and secretion of apolipoprotein A-I. Biochem. Soc. Transact. 1993, 21, 493-499.
8. Campbell, A. J., W. J. Busby & M. C. Robertson: Over 80 years and no evidence of coronary heart disease: Characteristics of a survivor group. J. Amer. Geriatr. Soc. 1993, 41, 1333-1338.
9. Chao, Y. S., C. B. Pickett, T. T. Yamin, L. S. Guo, A. Alberts & P. A. Kroon: Phenobarbital induces rat liver apolipoprotein A-I mRNA. Mol. Pharmacol. 1985, 27, 394-398.
10. Crook, D., R. Bmce, M. Worthington, D. Mulcahy, D. Petterson & V. Wynn: Effect of simvastatin on high density lipoprotein subfractions and apolipoproteins in type IIa hypercholesterolemia. Cardiovasc. Drugs Therap. 1992, 6, 633-639.
11. Durrington, P. N.: Effects of phenobarbitone on plasma apolipoprotein B and plasma high density lipoprotein cholesterol. Clin. Sci. 1979, 56, 501-504.
12. Duverger, N., H. Kruth, F. Emmanuel, J.-M. Caillaud, C. Viglietta, G. Castro, A. Tailleux, C. Fievet, J. P. Fruchart, L. M. Houdebine & P. Denefle: Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation 1996, 94, 713-717.
13. Ehnholm, C., K. Aho, J. K. Huttunen, E. Kostiainen, K. Mattila, J. Pikkarainen & K. Cantell: Effect of Interferon on plasma lipoproteins and on the activity of postheparin plasma lipases. Arteriosclerosis 1982, 2, 68-73.
14. Ettinger, B., G. D. Friedinan, T. Bush & C. P. Quesenberry: Reduced mortality associated with longterm postmenopausal estrogen therapy. Obstet. Gynecol. 1996, 87, 6-12.
15. Fears, R. (Ed): Pharmacological control of hyperlipidaemia. Barcelona, Prous, 1986.
16. Franceschiní, G., J. B. Werba, A. L. Dàcquarica, G. Gianfranceschi, S. Michelagnoli & C. R. Sirtori: Microsomal enzyme inducers raise plasma high-density lipoprotein cholesterol levels in healthy control subjects but not in patients with primary hypoalphalipoproteinemia. Clin. Pharmacol. Therap. 1995, 57, 434-440.
17. Frick, M. H., O. Elo, K. Haapa, O. P. Heinonen, P. Heinsalmi, P. Helo, J. K. Huttunen, P. Kaitaniemi, P. Koskinen, V. Manninen, H. Mäenpää, M. Mälkönen, M. Mänttäri, S. Norola, A. Pasternack, J. Pikkarainen, M. Romo, T. Sjöblom & E. Nikkilä: Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-age men with dyslipidemia. New Engl. J. Med. 1987, 317, 1237-1245.
18. Goerdt, C., M. Keith & H. B. Rubins: Effects of phenytoin on plasma high-density lipoprotein cholesterol levels in men with low levels of high-density lipoprotein cholesterol. J. Clin. Pharmacol. (United States) 1995, 35, 767-775.
19. Gordon, D. J., J. L. Probstfield, R. C. Garrison, J. D. Neaton, W. P. Castelli, J. D. Knoke, D. R. Jacobs Jr., S. Bangdiwala & H. A. Tyroler: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79, 8-15.
20. Hahn, S. & D. M. Goldberg: Modulation of lipoprotein production in HepG2 cells by fenofibrate and clofibrate. Biochem. Pharmacol. 1992, 43, 625-633.
21. Hall, I. H., M. A. Patrick & J. H. Maguire: Hypolipidemic activity in rodents of phenobarbital and related derivatives. Arch. Pharm. (Weinheim) 1990, 323, 579-586.
22. Heller, F. R., J. P. Desager & C. Harvengt: Changes in plasma activities of lipolytic enzymes and lipids of normolipidemic subjects given phenobarbital, a strong microsomal inducer, alone or in combination with fenofibrate. Int. J. Clin. Pharmacol. Ther. Toxicol. 1988, 26, 138-142.
23. Hertog, M. G., E. J. Feskens, P. Hollman, M. B. Katan & D. Kromhout: Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993, 324, 1007-1011.
24. Horsmanns, Y., J. P. Desager, V. van den Berge, M. Abrassart & C. Harvengt: Effects of simvastatin and pravastatin on 6-beta-hydroxycortisol excretion, a potential marker of cytochrome P-450-3A. Pharmacol. Res. (England) 1993, 28, 243-248.
25. Kashyap, M. L.: Basic considerations in the reversal of atherosclerosis: significance of high-density lipoprotein in stimulating reverse cholesterol tansport. Amer. J. Cardiol. 1989, 63, 56H-59H.
26. Lagrost, L.: Regulation of cholesteryl ester transfer protein (CETP) activity: review of in vitro and in vivo studies. Biochim. Biophys. Acta 1994, 1215, 209-236.
27. LaPorte, R., L. Valvo-Gerard, L. Kuller, W. Dai, M. Bates, J. Cresanta, K. Williams & D. Palkin: The relationship between alcohol consumption, liver enzymes and high-density lipoprotein cholesterol. Circulation 1981, 64 suppl. III, III-67-III-72.
28. Le, N.-A. H. N. Ginsberg: Heterogenity of apolipoprotein A-I metabolism in subjects with hypoalphalipoproteinemia with or without hypertriglyceridemia. Circulation 1989, 76, IV-325.
29. Luoma, P.: Yksilöllisten tekijöiden merkitys potilaiden lääkeaineenvaihdunnassa. In: Luettelo Suomen Akatemian Tutkimushankkeista 1978. Helsinki, Suomen Akatemia. 1979, pp. 129-130. In Finnish.
30. Luoma, P. V: Microsomal enzyme induction, lipoproteins and atherosclerosis. Pharmacology Toxicology 1988, 62, 243-249.
31. Luoma, P. V. C. Ehnholm, R. O. Pelkonen & E. A. Sotaniemi: Correlation of plasma high density lipoprotein cholesterol and apolipoproteins A-I and A-II to hepatic microsomal activity in man. In: Third Scandinavian Symposium on Atherosclerosis Research. Eds.: J. L. Kalliomäki, J. Viikari, A. Lehtonen & T. Rönnemaa. Pika Ltd., Turku, Finland, 1979a, 40A.
32. Luoma, P. V., V. Myllylä & E. Hokkanen: Plasma HDL cholesterol in epileptics in relation to anticonvulsant levels. Ahstracts of the 11th International Epilepsy Symposium, Firenze, 1979b, 171.
33. Luoma, P. V., E. A. Sotanieini, R.O. Pelkonen, A. Arranto & C. Ehnholm: Plasma high density lipoproteins and hepatic microsomal enzyme induction - Relation to histological changes in the liver. Eur. J. Clin. Pharmacol. 1982a, 23, 275-282.
34. Luoma, P. V., E. A. Sotaniemi, R. O. Pelkonen, M. Savolainen & C. Ehnholm: Induction and lipoproteins. Lancet 1982b, i, 625.
35. Luoma, P. V., M. J. Savolainen, E. A. Sotaniemi, R. O. Pelkonen, A. J. Arranto & C. Ehnholm: Plasma high density lipoproteins and liver lipids and proteins in man Relation to hepatic histology and microsomal enzyme induction. Acta med. scand. 1983, 214, 103-109.
36. Luoma, P. V., E. A. Sotaniemi, R. O. Pelkonen & C. Ehnholm: Alcohol, HDL cholesterol and liver microsomal enzyme induction. Lancet 1984, 1, 47.
37. Luoma, P. V., A. Rautio, J. Stengård, E. A. Sotaniemi & J. Marniemi: High-density lipoprotein subfractions, apolipoproteins and antipyrine clearance in normal subjects. Eur. J. Clin. Pharmacol. 1990, 38, 625-627.
38. MAAS investigators: Effect of simvastatin on coronary atheroina. the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994, 344, 633-638.
39. Mackness, M. I., B. Mackness, P. N. Durrington, P. W. Connelly & R. A. Hegele: Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 1996, 7, 69-76.
40. Malmendier, C. L. & C. Delcroix: Effect of alcohol intake on high and low density lipoprotein metabolism in healthy volunteers. Clin. Chim. Acta 1985, 152, 281-288.
41. Miller, M., R. G. Burgan, L. Osterlund, J. P. Segrest & D. W. Garber: A prospective, randomized trial of phenytoin in nonepileptic subjects with reduced HDL cholesterol. Arterioscler. Thromb. Vasc. Biol. 1995, 15, 2151-2156.
42. Miller, N. E (Ed): High density lipoproteins and atherosclerosis II. Elsevier Science Publishers, Amsterdam, 1989.
43. Miller, N. E.: Raising high density lipoprotein cholesterol. The biochemical pharmacology of reverse cholesterol transport. Biochem. Pharmacol. 1990, 40, 403-410.
44. Miyazaki, A. S. Sakunna, W. Morikawa, T. Takiue, F. Miake, T. Terano, M. Sakai, H. Hakamata, Y. I. Sakamoto, M. Naito, Y. Ryan, K. Takahashi, T. Ohta & S. Horiuchi: Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler. Thromb. Vasc. Biol. 1995, 15, 1882-1888.
45. Muuronen, A., M. Kaste, E. A. Nikkilä & E. M. Tolppanen: Mortality from ischaemic heart disease among patients using anticonvulsive drugs: a case - control study. Brit. Med. J. 1985, IV, 1481-1483.
46. Nikkilä, E. A., M. Kaste, C. Ehnholm & J. Viikari: Increase of serum high-density lipoprotein in phenytoin users. Brit. Med. J. 1978, 2, 99.
47. Paoletti, R., D. Kritchevsky & W.L. Holmes (Eds): Drugs affecting lipid metabolism Springer Berlin, 1987.
48. Park, B. K., N. R. Kitteringham & M. Pirmohamed: Relevance of induction of human drug metabolizing enzymes: pharmacological and toxicological implications. In: European Conference on Specifity and Variability in Drug Metabolism. European Commission, Directorate General XIII. Luxembourg 1995, pp. 169-187.
49. Pászty, C., N. Maeda, J. Verstuyft & E. M. Rubin: Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J. Clin. Invest. 1994, 94, 899-903.
50. Pichard, L., G. Gillet, C. Bonfils, J. Domergue, J.-P Thénot & P. Maurel: Predictability of drug metabolism from in vitro studies. In: European Conference on Specifity and Variability in Drug Metabolism. European Commission, Directorate General XIII, Luxembourg 1995, pp. 43-56.
51. Plump, A. S., C. J. Scott & J. L. Breslow: Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficent mouse. Proc. Natl. Acad Sci. USA 1994, 91, 9607-9611.
52. Poikolainen, K.: Alcohol and mortality: a review. J. Clin. Epidemiol. 1995, 48, 455-465.
53. Rader, D. J., J. R. Schaefer, P. Lohse, K. Ikewaki, F. Thomas, W. A. Harris, L. A. Zech, C. A. Dujovne & H. B. Brewer, Jr: Increased production of apolipoprotein A-I associated with elevated plasma levels of high-density lipoproteins, apolipoprotein A-I, and lipoprotein A-I in a patient with familial hyperalphalipoproteinemia. Metabolism 1993, 42, 1429-1434.
54. Ridell, D. R. & J. S. Owen: Inhibition of DP-induced platelet aggregation by apoE is not mediated by membrane cholesterol depletion. Thromb. Res. 1995, 80, 499-508.
55. Rosenson, R. S.: Beyond low-density lipoprotein cholesterol. Arch. Intern. Med. 1996, 156, 1278-1284.
56. Rubin, E. M., M. R. Krauss, E. A. Spangler, J. G. Verstuyft & M. S. Clift: Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I. Nature 1991, 353, 265-67.
57. Saku, K., P. S. Gartside, B. A. Hynd & M. L. Kashyap: Mechanism of action of gemfibrozil on lipoprotein metabolism. J. Clin Invest. 1985, 75, 1702-1712.
58. Salvador, R. A., C. Atkins, S. Haber, C. Kozma & A. Conney: Effect of phenobarbital and chlorcyclizine on the development of atheromatosis in the cholesterol-fed rabbit. Biochem. Pharmacol. 1970, 19, 1975-1981.
59. Savolainen, M. J., M. Hannuksela, S. Seppänen, K. Kervinen & Y. A. Kesäniemi: Increased high-density lipoprotein cholesterol concentration in alcoholics is related to low choleslerol ester transfer protein activity. Eur. J. Clin. Invest 1990, 20, 593-599.
60. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344, 1383-1389.
61. Schwartz, C. J., A. J. Valente, E. A. Sprague, J. L. Kelley, A. J. Cayette & J. Mowery: Atherosclerosis-potential targets for stabilization and regression. Circulation 1992, 86 suppl. III, III-117-III-123.
62. Sorci-Thomas, M., M. M. Prock, N. Dashti, F Johnson, L. L. Rudell & D. L. Williams: Apolipoprotein (apo) A-I production and mRNA abundance explain plasma apo A-I and high density lipoprotein differences between two non-human primate species with high and low susceptibilities to dietinduced hypercholesterolemia. J. Biol. Chem. 1988, 263, 5183-5189.
63. Staels, B., A. van Tol, J. C. Fruchart & J. Auwerx: Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat. Isr. J. Med. Sci. 1996, 32, 490-498.
64. Tam, S. P.: Effects of gemfibrozil and ketoconazole on human apolipoprotein A-I. B and E levels in two hepatoma cell lines. HepG2 and HepG3. Atherosclerosis 1991, 91, 51-61.
65. Tam, S. R: Effect of ethanol on lipoprotein secretion in two human hepatoma cell lines. HepG2 and HepG3. Alcohol Clin. Exp. Res. 1992, 16, 1021-1028.
66. Tam, S. P. & R. D. Deeley: Regulation of apolipoprotein A-I gene expression by phenobarbital in human hepatocarcinoma cell line, HepG3. Atherosclerosis 1994, 105, 235-243.
67. Vega, G. L. & S. M. Grundy: Lipoprotein responses to treatment with lovastatin, gemfibrozil and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch. Intern. Med. 1994, 154, 73-82.
68. Watts, G. F., B. Lewis, J. N. H. Brunt, E. S. Lewis, D. J. Coltart, L. D. R. Smith, J. I. Mann & A. W. Swan: Effects on coronary artery disease of lipid lowering diet, or diet plus cholestyramine. In St Thomas Atherosclerosis Regression Study (STARS) Lancet 1992, 339, 563-569.
69. Wilson, P. F. W., R. D. Abbott & W. P. Castelli: High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988, 8, 737-741.
70. Yaari, S. U. Goldbourt, S. Even-Zohar & H. N. Neufeld: Association of serum high density lipoprotein and total cholesterol with total, cardiovascular, and cancer mortality in a 7-year prospective study of 10000 men. Lancet 1981, i, 1011-1015.
71. Yamamoto, T., S. Takahashi, H. Nakaoko, M. Nakazato, M. Suda, Y. Moriwaki, T. Hada, M. Yanagisawa & K. Higashino: The effect of phenobarbital on human plasma lipids. Int. J. Clin. Pharmacol. Ther. Toxicol. 1989, 27, 463-466.